News

Article

AGC to Expand Chemical and API Capacity

The glass and chemical provider will expand its synthetic pharmaceutical intermediate and API production capacity at its plant in Chiba, Japan.

In a July 12, 2018 press release, AGC, a manufacturer of glass and chemicals, announced plans to expand facilities at its Chiba, Japan, site to increase the company’s synthetic pharmaceutical intermediate and API production capacity. 

According to the company, the new capacity will increase production at the Chiba plant tenfold and is set to come online in October 2019.

Previously, AGC primarily provided contract development and manufacturing services for the development stage of new drugs, but this new expansion will allow the company to provide end-to-end capability to also produce commercial drugs, the company reports. Additionally, the new facilities will be capable of producing hard-to-handle active ingredients, such as the highly potent APIs typically used in cancer therapy.

Source: AGC

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content